The observed loss and downregulation of BCMA expression on the surface of myeloma cells after CAR T-cell infusion in several clinical trials, highlights an imperative need to investigate the mechanism of resistance to BCMA CAR T-cell therapy. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.